Jeffrey G. Supko

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

Myrna R. Rosenfeld, Xiaobu Ye, Jeffrey G. Supko et al. · Autophagy · 2014 · 512 citations · Full text

Immunology, Cell Death, Pharmacotherapy +23

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

Rocio García‐Carbonero, Jeffrey G. Supko · PubMed · 2002 · 496 citations

Pathology, Pharmacotherapy, Anticancer Agents +19

Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent

Jeffrey G. Supko, Robert L. Hickman, Michael R. Grever et al. · Cancer Chemotherapy and Pharmacology · 1995 · 493 citations

Medicine, Pharmacology, Antitumor Agent +4

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

Ultan McDermott, Sreenath V. Sharma, Lori Dowell et al. · Proceedings of the National Academy of Sciences · 2007 · 355 citations · Full text

Engineering, Kinase Inhibitors, Cancer Biology +18